Business Standard

Abbott likely to withdraw high-end stents

Any drug brought under price control can be withdrawn after providing 6-month notice to NPPA

An Abbott company logo is pictured at the reception of its office in Mumbai
Premium

An Abbott company logo is pictured at the reception of its office in Mumbai

Veena Mani New Delhi
Abbott, market leader in premium cardiac stents, may withdraw its products from India following the National Pharmaceutical Pricing Authority’s (NPPA’s) order to cap prices last week. 

NPPA set a price cap of Rs 7,260 on bare metal stents and Rs 29,600 on drug eluting and biodegradable ones.

“Abbott may withdraw its Xience Alpine and its dissolving stent, Absorb,” said a distributor on the basis of informal communication. Abbott’s dissolving stent was priced at a little less than Rs 2 lakh before the price cap and the import price was Rs 42,125. 

"Abbott does not comment on market speculation," said a

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in